MRI outperformed micro-ultrasound in sensitivity and negative predictive value for prostate cancer detection. Micro-ultrasound offers a short learning curve and real-time lesion identification, ...
IsoPSA, a blood-based test, aids in diagnosing high-grade prostate cancer by analyzing PSA protein structural variants. FDA approval was based on a large-scale, prospective study and other validation ...
Alicia Morgans, MD, MPH, and Paul Sieber, MD, introduce the discussion, outlining goals to connect evolving mCRPC research with personalized immunotherapy practice.
Alicia Morgans, MD, MPH, and Paul Sieber, MD, introduce the discussion, outlining goals to connect evolving mCRPC research with personalized immunotherapy practice. The experts conclude with a forward ...
Most NMIBC patients rely on healthcare providers for treatment decisions, but desire more comprehensive discussions about options. Patients prefer treatments beyond chemotherapy, with 81% interested ...
Panelists discuss how recognizing and mitigating common biases in real-world prostate cancer data helps clinicians interpret findings responsibly and apply them effectively in patient care. Panelists ...
The ExactVu micro-ultrasound platform is noninferior to MRI in detecting clinically significant prostate cancer in biopsy-naïve men. Microultrasonography offers a cost-effective, in-office alternative ...
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
Gedatolisib and darolutamide combination targets PAM and AR pathways, potentially inducing a synergistic anti-tumor effect in mCRPC patients. Phase 1 trial with 38 patients showed promising safety, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback